China Antibody Pharmaceutical's IND application for anti-IL-17RB antibody accepted by FDA

On February 16, China Antibody Pharmaceutical Co.

Screenshot source: Reference [1]

According to the announcement, SM17 is a potential "first-in-class" humanized anti-IL-17RB monoclonal antibody for injection developed by China Antibody Pharmaceuticals

China Antibody Pharmaceuticals pointed out in the announcement that as a new approach for asthma treatment, therapies targeting upstream mediators of the Th2 inflammatory cytokine pathway (such as "vigilant") are expected to have a broader spectrum of pathological changes related to airway inflammation.

Public information shows that although approved severe asthma therapies (including biologics) can reduce the annual asthma exacerbation rate to a certain extent, there is still an unmet medical need for the effective treatment of severe asthma, especially those who do not respond to current therapies.

It is hoped that the follow-up studies of these new asthma therapies under development will proceed smoothly and bring new treatment options to patients as soon as possible

References:

[1] China Antibody Pharmaceutical Co.